| Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 T Vos, SS Lim, C Abbafati, KM Abbas, M Abbasi, M Abbasifard, ... The lancet 396 (10258), 1204-1222, 2020 | 7809 | 2020 |
| Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 CJL Murray, AY Aravkin, P Zheng, C Abbafati, KM Abbas, ... The lancet 396 (10258), 1223-1249, 2020 | 5688 | 2020 |
| Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic … H Wang, KM Abbas, M Abbasifard, M Abbasi-Kangevari, H Abbastabar, ... The Lancet 396 (10258), 1160-1203, 2020 | 1259 | 2020 |
| Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis … JM Kocarnik, K Compton, FE Dean, W Fu, BL Gaw, JD Harvey, ... JAMA oncology 8 (3), 420-444, 2022 | 1094 | 2022 |
| Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 C Abbafati, DB Machado, B Cislaghi, OM Salman, M Karanikolos, ... Deakin University, 2020 | 1047 | 2020 |
| The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease … S Alatab, SG Sepanlou, K Ikuta, H Vahedi, C Bisignano, S Safiri, ... The Lancet gastroenterology & hepatology 5 (1), 17-30, 2020 | 917 | 2020 |
| Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021 KL Ong, LK Stafford, SA McLaughlin, EJ Boyko, SE Vollset, AE Smith, ... The Lancet 402 (10397), 203-234, 2023 | 709 | 2023 |
| Five insights from the global burden of disease study 2019 CJL Murray, C Abbafati, KM Abbas, M Abbasi, M Abbasi-Kangevari, ... The Lancet 396 (10258), 1135-1159, 2020 | 620 | 2020 |
| Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990–2019: a systematic analysis for the Global … R Lozano, N Fullman, JE Mumford, M Knight, CM Barthelemy, C Abbafati, ... The Lancet 396 (10258), 1250-1284, 2020 | 540 | 2020 |
| The global, regional, and national burden of stomach cancer in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease study 2017 A Etemadi, S Safiri, SG Sepanlou, K Ikuta, C Bisignano, R Shakeri, ... The lancet Gastroenterology & hepatology 5 (1), 42-54, 2020 | 503 | 2020 |
| The global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 2019 KB Tran, JJ Lang, K Compton, R Xu, AR Acheson, HJ Henrikson, ... The Lancet 400 (10352), 563-591, 2022 | 429 | 2022 |
| X-linked recessive TLR7 deficiency in~ 1% of men under 60 years old with life-threatening COVID-19 T Asano, B Boisson, F Onodi, D Matuozzo, M Moncada-Velez, ... Science immunology 6 (62), eabl4348, 2021 | 342 | 2021 |
| Global, regional, and national progress towards Sustainable Development Goal 3.2 for neonatal and child health: all-cause and cause-specific mortality findings from the Global … KR Paulson, AM Kamath, T Alam, K Bienhoff, GG Abady, J Abbas, ... The Lancet 398 (10303), 870-905, 2021 | 331 | 2021 |
| Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 GBD Collaborators, J Ärnlöv The Lancet 396 (10258), 1223-1249, 2020 | 313 | 2020 |
| Disease evolution and response to rapamycin in activated phosphoinositide 3-kinase δ syndrome: the european society for immunodeficiencies-activated phosphoinositide 3-kinase δ … ME Maccari, H Abolhassani, A Aghamohammadi, A Aiuti, O Aleinikova, ... Frontiers in immunology 9, 543, 2018 | 290 | 2018 |
| IgA deficiency: correlation between clinical and immunological phenotypes A Aghamohammadi, T Cheraghi, M Gharagozlou, M Movahedi, N Rezaei, ... Journal of clinical immunology 29, 130-136, 2009 | 282 | 2009 |
| Selective IgA deficiency: epidemiology, pathogenesis, clinical phenotype, diagnosis, prognosis and management R Yazdani, G Azizi, H Abolhassani, A Aghamohammadi Scandinavian journal of immunology 85 (1), 3-12, 2017 | 231 | 2017 |
| Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6–8 months after the infection N Sherina, A Piralla, L Du, H Wan, M Kumagai-Braesch, J Andréll, ... Med 2 (3), 281-295. e4, 2021 | 210 | 2021 |
| Spectrum of Phenotypes Associated with Mutations in LRBA OK Alkhairy, H Abolhassani, N Rezaei, M Fang, KK Andersen, ... Journal of clinical immunology 36, 33-45, 2016 | 210 | 2016 |
| Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis H Abolhassani, MS Sadaghiani, A Aghamohammadi, HD Ochs, N Rezaei Journal of clinical immunology 32, 1180-1192, 2012 | 210 | 2012 |
Nima RezaeiTehran University of Medical Sciences; Universal Scientific Education and Research Network (USERN)在 tums.ac.ir 的电子邮件经过验证
